Copyright
©The Author(s) 2017.
World J Methodol. Mar 26, 2017; 7(1): 25-32
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.25
Published online Mar 26, 2017. doi: 10.5662/wjm.v7.i1.25
Table 1 Baseline characteristics of all patients
Baseline characteristics | Number of patients underwent patch testing n = 24 (%) |
Gender | |
Male | 13 (54.2) |
Female | 11 (45.8) |
M:F | 1:1.8 |
Age (yr) | |
Range | 18-75 |
Mean ± SD | 45.70 ± 16.29 |
18-30 | 4 (16.7) |
31-50 | 12 (50) |
51-70 | 6 (25) |
> 70 | 2 (8.3) |
Time interval (d) between drug intake and ACDRs | |
Range | 7-45 |
Mean ± SD | 22.54 ± 12.19 |
Implicated drugs | |
Phenytoin | 14 (58.3) |
Carbamazepine | 9 (37.5) |
Phenobarbitone | 2 (8.3) |
Lamotrigine | 1 (4.7) |
Phenytoin1 + Carbamazepine | 1 (4.7) |
Phenytoin1 + Phenobarbitone | 1 (4.7) |
Clinical spectrum of ACDRs | |
DRESS | 18 (75) |
SJS-TEN overlap | 2 (8.3) |
TEN | 2 (8.3) |
SJS | 1 (4.2) |
Lichenoid drug eruption | 1 (4.2) |
Time interval (mo) between complete recovery from ACDRs and Patch test | |
Range | 1-24 |
Mean ± SD | 9.62 ± 6.62 |
Table 2 Clinical patterns of adverse cutaneous drug reaction and individual implicated anticonvulsants
Implicated drugs | Clinical patterns (n = 24 ) | ||||
DRESS | SJS | SJS-TEN overlap | TEN | Lichenoid drug eruption | |
Phenytoin | 9 | 1 | 1 | 1 | - |
Carbamazepine | 6 | - | - | 1 | 1 |
Phenytoin + Carbamazepine | - | - | 1 | - | - |
Phenytoin + Phenobarbitone | 1 | - | - | - | - |
Lamotrigine | - | - | 1 | - | - |
Phenobarbitone | 1 | - | - | - | - |
Sodium valproate + Lamotrigine | - | - | - | - | - |
Table 3 Positive drug patch test results
Case No | Age (yr) and Sex | Clinical diagnosis | Implicated drug | Interval between drug rash and patch test (mo) | Patch test results (Grades) | Cross reactions (Grades) | Irritant reaction at D2 |
1 | 65 F | DRESS | Carbamazepine | 7 | Carbamazepine (2+) with 10%, 20%, 30% | Sodium valproate (1+) with 20%, 30% | - |
2 | 60 F | DRESS | Carbamazepine | 6 | Carbamazepine (3+) with 20%, 30% | Lamotrigine (3+) with 30% | Carbamazepine 10%, Lamotrigine 10%, Sodium valproate 10%, 30% Phenobarbitone 30% |
3 | 55 F | DRESS | Carbamazepine | 5 | Carbamazepine (1+) with 30% | Sodium valproate (2+) with 10%, 30% Lamotrigine (1+) with 10%, 20%, 30% | Carbamazepine 10% and 20%, Phenobarbitone 10%, 30% and Sodium valproate 20% |
4 | 52 M | Lichenoid drug eruptions | Carbamazepine | 6 | Carbamazepine (2+) with 10%, 20%, 30% | Phenobarbitone (2+) with 10%, 20%, 30% | Phenytoin 20%, Sodium valproate 20% and Lamotrigine 10% |
5 | 48 M | DRESS | Phenobarbitone | 9 | Phenobarbitone (3+) with 10%, 20%, 30% | Phenytoin (3+) with 10%, 20%, 30% Carbamazepine (2+) with 30% Sodium valproate (3+) with 10%, 30% Lamotrigine (1+) with 30% | - |
6 | 32F | DRESS | Carbamazepine | 6 | Carbamazepine (3+) with 10%, 20%, 30% | Sodium valproate (1+) with 10%, Lamotrigine (3+) with 10%, 30% Phenobarbitone (2+) with 10%, 30% | Phenytoin 10% |
7 | 31 M | DRESS | Phenytoin | 8 | Phenytoin (1+) with 30% | Lamotrigine (1+) with 30% | - |
8 | 26 M | DRESS | Phenytoin | 6 | Phenytoin (1+) with 30% | - | - |
9 | 63 M | DRESS | Carbamazepine | 4 | Carbamazepine (2+) with 10% | Lamotrigine (1+) with 30% | - |
10 | 31 M | DRESS | Phenytoin + Phenobarbitone | 8 | Phenytoin (3+) and Phenobarbitone (3+) with 10%, 20%, 30% | Lamotrigine (1+) with 30% | Sodium valproate 10% and 30%, |
11 | 43 F | DRESS | Phenytoin | 4 | Phenytoin (2+) with 10%, 30% | Phenobarbitone (2+) with 10%, 30% | Carbamazepine 30% |
12 | 75 F | DRESS | Phenytoin | 5 | Phenytoin (2+) with 20%, 30% | Phenobarbitone (2+) with 10%, 20%, Sodium valproate (2+) with 10%, 20%, 30% | Phenytoin 10% |
13 | 56 M | DRESS | Phenytoin | 1 | - | - | Sodium valproate 10%, 20%, 30% |
14 | 60 M | DRESS | Phenytoin | 1 | - | - | Sodium valproate 10%, 20%, 30% |
Table 4 Patch test reactions with different concentrations of drugs
Case No | Clinical diagnosis | Carbamazepine | Phenytoin | Phenobarbitone | Lamotrigine | Sodium valproate | ||||||||||
10% | 20% | 30% | 10% | 20% | 30% | 10% | 20% | 30% | 10% | 20% | 30% | 10% | 20% | 30% | ||
1 | DRESS | 2+ | 2+ | 2+ | - | - | - | - | - | - | - | - | - | - | 1+ | 1+ |
2 | DRESS | - | 3+ | 3+ | - | - | - | - | - | - | - | - | 3+ | - | - | - |
3 | DRESS | - | - | 1+ | - | - | - | - | - | - | 1+ | 1+ | 1+ | 2+ | - | 2+ |
4 | Lichenoid drug eruptions | 2+ | 2+ | 2+ | - | - | - | 2+ | 2+ | 2+ | - | - | - | - | - | - |
5 | DRESS | - | - | 2+ | 3+ | 3+ | 3+ | 3+ | 3+ | 3+ | - | - | 1+ | 3+ | - | 3+ |
6 | DRESS | 3+ | 3+ | 3+ | - | - | - | 2+ | - | 2+ | 3+ | - | 3+ | 1+ | - | - |
7 | DRESS | - | - | - | - | - | 1+ | - | - | - | - | - | 1+ | - | - | - |
8 | DRESS | - | - | - | - | - | 1+ | - | - | - | - | - | - | - | - | - |
9 | DRESS | 2+ | - | - | - | - | - | - | - | - | - | - | 1+ | - | - | - |
10 | DRESS | - | - | - | 3+ | 3+ | 3+ | 3+ | 3+ | 3+ | - | - | 1+ | - | -- | - |
11 | DRESS | - | - | - | 2+ | - | 2+ | 2+ | - | 2+ | - | - | - | - | - | - |
12 | DRESS | - | - | - | - | 2+ | 2+ | 2+ | 2+ | - | - | - | - | 2+ | 2+ | 2+ |
13 | DRESS | - | - | - | - | - | - | - | - | - | - | - | - | IR | IR | IR |
14 | DRESS | - | - | - | - | - | - | - | - | - | - | - | - | IR | IR | IR |
Total | 4 | 4 | 6 | 3 | 3 | 6 | 6 | 4 | 5 | 2 | 1 | 7 | 4 | 2 | 4 |
- Citation: Shiny TN, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Sharma R. Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: A preliminary report. World J Methodol 2017; 7(1): 25-32
- URL: https://www.wjgnet.com/2222-0682/full/v7/i1/25.htm
- DOI: https://dx.doi.org/10.5662/wjm.v7.i1.25